Member Info for BigDave13

Channel 4 tonight 7:30pm
Unreported World
In Chiapas in Mexico, where Coca-Cola is king, Guillermo Galdos meets families in the thick of a diabetes crisis - a deadly mix of Covid and sugar sending people to early graves.

RNS from 3rd Aug also highlights another 3 new team members to market activities into Asia. Now into Dubai and potentially may increase team members further to continue growth. Key question is how quickly can all these new hires generate revenues to cover the increase staff/office/admin costs plus the existing loss profile? Would be good to get your further thoughts once you have done a review.

I just feel that there could be a placing here by year end on this one. This is based on Gross Profit vs Admin Expenses (cash loss of c.£760k) compared to Cash on Hand (c.£950k). New office in Dubai will increase expenses, how quickly can they generate revenues to cover this and then some? I do like the business but think it may take some time to mature into a cash positive business, maybe Vela can participate if called upon and get that average down.

I wonder why it was kept so hush hush. Vela need to update website with RBBS and CODE details now.

https://www.ruralbroadbandsolutions.com/

https://www.aquis.eu/aquis-stock-exchange/for-investors/announcements?view_news_id=3250652

New Contract

In recent years the customer has ordered approximately $4 million of components from the Group per annum and with this agreement in place the MTI Board believe that the level of future orders is likely to be higher.

https://www.lse.co.uk/rns/MWE/strategic-customer-agreement-xbeg8vmnv5umfbm.html

Good summary. but don't dis Rural Broadband Solutions PLC. Up 40%, could be our best investment :-)

The work of SGS was recognised at a reception at No. 10 a couple of weeks back, alongside the UK-United Arab Emirates prosperity and innovation partnership. There is no reason to think that SGS are not fully engaged with the Trial or won't see it thru to deal/next trials etc. Any negativity here is due to the perceived commercialisation deal delay but latest is that discussions are progressing and so we need to sit tight for now and we will be updated when there is some news to announce.

As frustrating as this perceived delay is, we need to wait for the commercialisation discussions to play out to see where we land. Vela can only get a return if a 3rd party buys or licences the drug - nothing to indicate this will not happen. The recent article about the SGS visit to No. 10 indicated that there was further results to analyse and a peer review, we do not know if a deal is subject to these actions. I am sure SGS/EML are working diligently on this, our timelines are not factor.

Not expecting anything specific but wouldn't it be great if we got some sort of positive news re SGS progress, we need it. Maybe an indication of plans for the existing cash, any near term potential investment opportunities. Wouldn't mind some clarification on the status of the non listed entities which we never hear about Weshop, Revolve & Disruptive Tech - any value/prospects or are they worthless and written off to Nil value?

Yep, year end is 31 March so Accounts due by 30 Sept i.e. tomorrow. I note that last year they dropped on 28/09 at 4.53pm so could land anytime from now.

This is quite an astonishing valuation for Multiverse who has raised $194 million to date and placed over 5,000 apprentices. I think it bodes well for CODE which has its own Apprenticeship programme amongst various other revenue generating activities. 2nd largest investment to date, could pay off big time as CODE continues to expand and grow throughout the UK. Interim results were released today and provides a good summary.

https://www.standard.co.uk/business/euan-blair-multiverse-apprenticeships-startup-raises-130-million-to-see-875-million-valuation-b957675.html

@Hector, use the filter function and green list these nutters, makes the Board oh so more enjoyable now.
@DShox, I think you may be right there, another day closer, can't be too long now. Think about SGS visit to No.10 to recognise their work alongside UAE innovation partnership. Watch out for any further hints/news in Accounts due by Thurs.

I think if a commercial deal happens, then that would come with some sort of upfront payment together with a recurring licence payment. Funds could then be re-invested in manufacture/trials etc if required, alongside current cash. The burning question at the moment is when do we find out news?

Otherwise, in the near term, if JN can pump the SP north of 0.15p by 23 Oct, then potential for another £1.4m from warrants exercise. And if it does get there, the 0.125p warrants could go too, another £1m. So £2.4 is there for the taking, comes with dilution but at a far better price than a placing down at these depressing prices. Close to £5m would then provide JN with a range of investment opportunities.

All to play for, IMO, gla

Accounts due by this Thursday so hopefully that will include some progress updates. Agree on the cash in bank, funds raised in Feb then sat on for months til the CODE investment. With recent warrant monies,cash should now be around £2.4m so I wonder what the plans are. If a commercial deal eventuates and it results in a big pay day then we could well see some exciting things come to fruition.

Actually the RNS used an And/Or statement.

Which means that commercialisation is an option but may not proceed if the "Or" bit of the statement applies.

On the same basis it does mean that further clinical trials will proceed but were not defined as Phase II or Phase III, could be either as I see it.

Posted on CSFS board:

https://www.proactiveinvestors.co.uk/companies/news/961431/cornerstone-fs-tap-into-sizeable-and-growing-market-in-middle-east-by-opening-office-in-dubai-961431.html

Yep, geopolitics at play here. France, Germany and EU trashing the not for profit AZ vaccine and US has still not provided EUA for it. UK recently cancelled the Manufacture of French vaccine onshore and so it goes on. I believe that Pfizer now have full FDA approval and the other vaccines are probably in progress. Lots of money to be made if you play the game right. A generic treatment may be some time off, AZD1656 probably limited in use in first instance until fuller phase III trials. imo.

EASD conference commences tomorrow. Click on Programme and you can see that there are several sessions covering covid although I see nothing from the Arcadia trial but you never know.
https://www.easd.org/annual-meeting/easd-2021.html

Not directly related, but an interesting read
https://inews.co.uk/news/a-common-osteoporosis-drug-can-prevent-diabetes-in-half-who-take-it-1219327

The Group recognised a loss before tax of £1.2m for the first half of 2021. As at 30 June 2021, the Group had cash and cash equivalents of £951k. Trade and other receivables materially less than Trade and other payables.

Expansion will need to be funded from somewhere, either a large increase in H2 revenues/gross profit or otherwise another fundraise will be on the cards at some stage. Anyone got any thoughts on this investment? I like the Business though will take some time to mature, maybe an opportunity for Vela to deploy some £££ if offered and average down a little.

Lots of good things to look forward to as you say. Per previous RNS, there are still a few items outstanding though, incl fundraising, placing and GM approval. Would be great if all wrapped up prior to year end.